JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Identification of prognostic indicator based on hypoxia-related lncRNAs analysis in lung adenocarcinoma

  • 0Department of Pathology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China.
Malawi Medical Journal : the Journal of Medical Association of Malawi +

|

February 28, 2025

|

February 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study identified nine hypoxia-related long noncoding RNAs (lncRNAs) as a signature to predict lung adenocarcinoma (LUAD) survival. This signature serves as a potential biomarker and therapeutic target for LUAD patients.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • Lung adenocarcinoma (LUAD) lacks systematic studies on hypoxia-related long noncoding RNA (lncRNA) signatures for survival prediction.
  • Establishing such signatures is crucial for identifying novel prognostic biomarkers in LUAD.

Purpose Of The Study

  • To develop a hypoxia-related lncRNA signature for predicting the prognosis of LUAD patients.
  • To identify potential novel biomarkers for LUAD patient survival.

Main Methods

  • Utilized The Cancer Genome Atlas (TCGA) database for lncRNA expression profiles from 535 LUAD samples.
  • Employed coexpression network analysis, univariate Cox regression, Lasso regression, and multivariate Cox regression to identify and validate prognostic lncRNAs.
  • Developed a risk score based on the identified signature and assessed its independence as a prognostic factor.

Main Results

  • Identified a signature comprising nine prognostic hypoxia-related lncRNAs (LINC01150, AC010980.2, AL606489.1, AL034397.3, LINC00460, LINC02081, FAM83AAS1, AL365181.2, AC026355.1).
  • The high-risk group exhibited significantly shorter overall survival (OS) compared to the low-risk group (P = 3.329e-09).
  • The risk score was a significant independent prognostic factor for LUAD patients (HR = 1.449, P < 0.001).

Conclusions

  • The developed nine-lncRNA signature shows potential as molecular biomarkers for LUAD.
  • These hypoxia-related lncRNAs may serve as valuable therapeutic targets for LUAD patients.

Keywords: